Eledon Pharmaceuticals, Inc. (ELDN) Executive Pay versus Performance: Other Disclosures, 2023

Eledon Pharmaceuticals, Inc. Other Executive Compensation Disclosures

Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.

• 2023-05-01: Disclosure Pay versus Performance Table; Period 2022-01-01..2022-12-31; Value The following table sets forth information regarding the Company’s performance and the “compensation actually paid” ("CAP") to our named executive officers, as calculated in accordance with SEC disclosure rules: Value of Initial Fixed $100 Investment Based on: (3) Year Summary Compensation….
• 2023-05-01: Disclosure Named Executive Officers Footnote; Period 2022-01-01..2022-12-31; Value (1) Amounts reported in this column represent (i) the total compensation reported in the Summary Compensation Table for the year indicated for Dr. Gros and (ii) the average of the total compensation reported in the Summary Compensation Table for the year indicated for the Company's named executive o….
• 2023-05-01: Disclosure Additional402v Disclosure; Period 2022-01-01..2022-12-31; Value (2) The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s named executive officers. Compensation Actually Paid reflects the Summary Compensation Ta….
• 2023-05-01: Disclosure Total Shareholder Return Vs Peer Group; Period 2022-01-01..2022-12-31; Value (3) Total Shareholder Return (TSR) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share pr….